Trial Profile
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 May 2015
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 23 Apr 2015 New trial record